CEL-SCI to Launch FDA Registration-Enabling Phase 3 Confirmatory Study to Bring Multikine® to Market for Newly Diagnosed Head and Neck Cancer

CEL-SCI plans to launch an FDA registration-enabling Phase 3 confirmatory study for Multikine to support bringing the therapy to market for newly diagnosed head and neck cancer. The milestone is a positive regulatory development, though it is not yet approval or commercialization. Net impact is likely to be modest for the near term, with more defined upside contingent on Phase 3 outcomes and subsequent FDA review.

Analysis

CEL-SCI plans to launch an FDA registration-enabling Phase 3 confirmatory study for Multikine to support bringing the therapy to market for newly diagnosed head and neck cancer. The milestone is a positive regulatory development, though it is not yet approval or commercialization. Net impact is likely to be modest for the near term, with more defined upside contingent on Phase 3 outcomes and subsequent FDA review.